Premium
Fibrinolytic Enhancement by Stanozolol: A Double Blind Trial
Author(s) -
Davidson J. F.,
Lochhead M.,
McDonald G. A.,
McNicol G. P.
Publication year - 1972
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1972.tb05701.x
Subject(s) - stanozolol , medicine , fibrinolysis , phenformin , ischaemic heart disease , placebo , gastroenterology , pathology , alternative medicine , metformin , anabolism , insulin
S ummary Thirty‐four men with ischaemic heart disease were given 10 mg stanozolol per day, 10 mg stanozolol plus 100 mg phenformin per day, or a placebo for 12 mth, in a double blind randomized study. A panel of fibrinolytic and coagulation tests was performed at monthly intervals. Throughout the study the groups on active treatment showed significant enhancement of plasma fibrinolytic activity compared with their base‐line values, and compared with the placebo group. No significant difference was found in the enhancement of fibrinolysis wliich was produced by either active treatment regimens, and it is concluded that 10 mg stanozolol daily‐is as effective as 10 mg stanozolol plus 100 mg phenformin daily in increasing plasma fibrinolytic activity in men with ischaemic heart disease.